Package Leaflet: Information for the Patient
Ofev 150mg Soft Capsules
nintedanib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
Ofev contains the active substance nintedanib, a medicine that belongs to the class of drugs known as tyrosine kinase inhibitors, and is used to treat the following diseases:
Idiopathic Pulmonary Fibrosis (IPF) in adults
IPF is a disease that causes thickening, hardening, and scarring of the tissue in your lungs over time. As a result, scarring reduces the ability to transfer oxygen from the lungs to the bloodstream, making it difficult to breathe deeply. Ofev helps reduce the occurrence of further scarring and hardening of the lungs.
Other chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype in adults
In addition to IPF, there are other disorders in which the tissue in your lungs becomes thickened, hardened, and scarred over time (pulmonary fibrosis) and continues to worsen (progressive phenotype). Some examples of these disorders are hypersensitivity pneumonitis, autoimmune ILD (such as ILD associated with rheumatoid arthritis), idiopathic nonspecific interstitial pneumonia, idiopathic unclassifiable interstitial pneumonia, and other ILD. Ofev helps reduce new scarring and hardening of the lungs.
Fibrosing interstitial lung diseases (ILD) in children and adolescents from 6 to 17 years of age
Pulmonary fibrosis can occur in patients with childhood interstitial lung disease. In this case, the tissue in the lungs of children and adolescents becomes thickened, hardened, and scarred over time. Ofev helps reduce the occurrence of further scarring and hardening of the lungs.
Interstitial lung disease associated with systemic sclerosis (SSc-ILD) in adults, adolescents, and children 6 years of age and older
Systemic sclerosis (SSc), also known as scleroderma (and juvenile systemic sclerosis in children and adolescents), is a rare chronic autoimmune disease that affects the connective tissue in many parts of the body. SSc causes fibrosis (scarring and hardening) of the skin and other internal organs, such as the lungs. When the lungs are affected by fibrosis, it is called interstitial lung disease (ILD) and the disease is called SSc-ILD. Fibrosis in the lungs reduces the ability to transfer oxygen to the bloodstream and reduces the ability to breathe. Ofev helps reduce the occurrence of further scarring and hardening of the lungs.
Do not take Ofev
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Ofev
Based on this information, your doctor may perform some blood tests, for example, to check your liver function. Your doctor will discuss the results of these tests with you to decide if you can take Ofev.
Tell your doctor immediately while you are taking this medicine
Children and adolescents
Children under 6 years of age must not take Ofev.
Your doctor may perform regular dental examinations at least every 6 months until the completion of tooth development and monitor your growth once a year (bone imaging study) while you are taking this medicine.
Other medicines and Ofev
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including herbal medicines and medicines obtained without a prescription.
Ofev may interact with other medicines. The following medicines may
increase the levels of nintedanib in your blood and, therefore, increase the risk of side effects (see section 4, "Possible side effects"):
The following medicines are examples that may decrease the levels of nintedanib in your blood and, therefore, reduce the effectiveness of Ofev:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take this medicine during pregnancy, as it may harm the fetus and cause birth defects.
A pregnancy test must be performed to ensure you are not pregnant before starting treatment with Ofev. Talk to your doctor.
Contraception
Breastfeeding
Do not breastfeed your baby during treatment with Ofev, as it may harm the baby.
Driving and using machines
Ofev has a minor influence on the ability to drive and use machines. Do not drive or use machines if you feel dizzy.
Ofev contains soy lecithin
If you are allergic to soy or peanuts, do not take this medicine (see section 2, "Do not take Ofev").
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Take the capsules twice a day, with about 12 hours in between, and approximately at the same time of day; for example, one capsule in the morning and one capsule in the evening. This will ensure that you maintain a constant level of nintedanib in your blood. Swallow the capsules whole with water, without chewing them. It is recommended to take the capsules with food, i.e., during meals or immediately before or after meals. Do not open or break the capsule (see section 5, "Storage of Ofev").
To make it easier to swallow the capsules, you can take them with a small amount (one teaspoon) of a soft cold or room-temperature food, such as apple sauce or chocolate pudding. Swallow the capsules immediately and do not chew them to ensure they remain intact.
Adults
The recommended dose is one 150 mg capsule twice a day (a total of 300 mg per day).
Do not take more than the recommended dose of two Ofev 150 mg capsules per day.
If you do not tolerate the recommended dose of two Ofev 150 mg capsules per day (see possible side effects in section 4), your doctor may reduce your daily dose of Ofev. Do not reduce the dose or stop treatment yourself without consulting your doctor first.
Your doctor may reduce the recommended dose to 100 mg twice a day (a total of 200 mg per day). In this case, your doctor will prescribe Ofev 100 mg capsules for your treatment. Do not take more than the recommended dose of two Ofev 100 mg capsules per day if your daily dose has been reduced to 200 mg per day.
Use in children and adolescents
The recommended dose depends on the patient's weight.
Tell your doctor if the patient's weight is less than 13.5 kg at any time during treatment.
Tell your doctor if you have liver problems.
Your doctor will determine the correct dose. Your doctor may adjust the dose during the course of treatment.
If you do not tolerate the recommended daily dose of Ofev capsules (see possible side effects in section 4), your doctor may reduce the daily dose of Ofev.
Do not reduce the dose or stop treatment yourself without consulting your doctor first.
Dosing based on weight for Ofev capsules in children and adolescents:
Weight range in kilograms (kg) | Ofev dose in milligrams (mg) |
13.5-22.9 kg | 50 mg (two 25 mg capsules) twice a day |
23.0-33.4 kg | 75 mg (three 25 mg capsules) twice a day |
33.5-57.4 kg | 100 mg (one 100 mg capsule or four 25 mg capsules) twice a day |
57.5 kg or more | 150 mg (one 150 mg capsule or six 25 mg capsules) twice a day |
If you take more Ofev than you should
Contact your doctor or pharmacist immediately.
If you forget to take Ofev
Do not take two capsules together if you have missed your previous dose. You should take your next dose of Ofev according to the schedule established and recommended by your doctor or pharmacist.
If you stop taking Ofev
Do not stop taking Ofev without talking to your doctor first. It is important to take this medicine every day while your doctor prescribes it.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
You should pay special attention if you experience the following adverse effects during treatment with Ofev:
Diarrhea(very frequent, may affect more than 1in 10people):
Diarrhea can cause dehydration: a loss of fluids and important salts from the body (electrolytes, such as sodium or potassium). If you experience the first symptoms of diarrhea, drink plenty of fluids and consult your doctor immediately. Start appropriate anti-diarrheal treatment as soon as possible, for example, by taking loperamide.
The following adverse effects have also been observed during treatment with this medicine.
Consult your doctor if you experience any type of adverse effect.
Idiopathic Pulmonary Fibrosis (IPF)
Very frequent adverse effects (may affect more than 1in 10people)
Frequent adverse effects (may affect up to 1in 10people)
Infrequent adverse effects (may affect up to 1in 100people)
Frequency not known (cannot be estimated from available data)
Other Chronic Fibrosing Interstitial Lung Diseases (ILDs)
Very frequent adverse effects (may affect more than 1in 10people)
Frequent adverse effects (may affect up to 1in 10people)
Infrequent adverse effects (may affect up to 1in 100people)
Frequency not known (cannot be estimated from available data)
Very frequent adverse effects (may affect more than 1in 10people)
Frequent adverse effects (may affect up to 1in 10people)
Infrequent adverse effects (may affect up to 1in 100people)
Frequency not known (cannot be estimated from available data)
Fibrosing Interstitial Lung Diseases (ILDs) in Children and Adolescents
Adverse effects in children and adolescents were similar to those in adult patients.
Report to your doctor if you experience any type of adverse effect.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton and blister. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Store in the original packaging to protect from moisture.
Do not use this medicine if you notice that the blister containing the capsules is open or that a capsule is broken.
If you come into contact with the contents of the capsule, wash your hands immediately with plenty of water (see section 3, "How to take Ofev").
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Ofev Composition
Capsule content: medium-chain triglycerides, hard fat, soy lecithin (E322) (see section 2, "Do not take Ofev")
Capsule shell: gelatin, glycerol (85%), titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172)
Product Appearance and Package Contents
Ofev 150 mg capsules are soft gelatin capsules, oblong, opaque, and brown in color (approximately 18 x 7 mm), marked on one side with the Boehringer Ingelheim company logo and the number "150".
There are two package sizes for Ofev 150 mg capsules:
Not all package sizes may be marketed.
Marketing Authorization Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
You can obtain more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium Boehringer Ingelheim SComm Tel: +32 2 773 33 11 | Lithuania Boehringer Ingelheim RCV GmbH & Co KG Lithuanian branch Tel: +370 5 2595942 |
Luxembourg Boehringer Ingelheim SComm Tel: +32 2 773 33 11 | |
Czech Republic Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Hungary Boehringer Ingelheim RCV GmbH & Co KG Hungarian branch Tel: +36 1 299 89 00 |
Denmark Boehringer Ingelheim Danmark A/S Tel: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Germany Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 | Netherlands Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Estonia Boehringer Ingelheim RCV GmbH & Co KG Estonian branch Tel: +372 612 8000 | Norway Boehringer Ingelheim Danmark Norwegian branch Tel: +47 66 76 13 00 |
Greece Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε. Tel: +30 2 10 89 06 300 | Austria Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
Spain Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Poland Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tel: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Croatia Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | Romania Boehringer Ingelheim RCV GmbH & Co KG Viena – Bucharest branch Tel: +40 21 302 2800 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenia Boehringer Ingelheim RCV GmbH & Co KG Ljubljana branch Tel: +386 1 586 40 00 |
Iceland Vistor ehf. Tel: +354 535 7000 | Slovakia Boehringer Ingelheim RCV GmbH & Co KG organizational unit Tel: +421 2 5810 1211 |
Italy Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Finland Boehringer Ingelheim Finland Ky Tel: +358 10 3102 800 |
Cyprus Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε. Tel: +30 2 10 89 06 300 | Sweden Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvia Boehringer Ingelheim RCV GmbH & Co KG Latvian branch Tel: +371 67 240 011 |
Date of Last Revision of this Leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.